MHRA concludes review of Avacopan Vifor following reassessment of benefit-risk balance
The MHRA has completed its review of Avacopan, marketed by Vifor, after re-evaluating its benefit-risk balance for use in patients with ANCA-associated vas…
Impact analysis · 39/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The MHRA has completed its review of Avacopan, marketed by Vifor, after re-evaluating its benefit-risk balance for use in patients with ANCA-associated vasculitis. The review found that the overall benefit-risk profile remains positive, and no regulatory action is required at this time. Avacopan can continue to be used as authorised in the UK.
Quantitative evidence
- 1 substance reviewed: Avacopan
- 1 sponsor: Vifor
- Review completion date: 2026-09-01
- Number of UK patients treated
- Postmarketing signal incidence rates
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
Avacopan remains authorised in ANCA-associated vasculitis based on current benefit-risk assessment by the MHRA.
Market context
Continued availability supports Vifor’s position in the rare renal disease treatment market in the UK.
Legal and regulatory context
The benefit-risk reassessment did not trigger any changes to Avacopan's authorisation under present MHRA frameworks.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- c50484181c0e7a166f616b1017a3dc7dcac61d7d2dda847b7f25f479acc1fdfa
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-09-01T130925Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.